EVAX

Investor Moves

Name	Value	Action	Change	Price	Last Price
Steven CohenPoint72 $-157.9K ExitQ1 2026 $158k -- $3.08

News

globenewswire.comEvaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congressglobenewswire.comMay 12

seekingalpha.comEvaxion A/S (EVAX) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 7

globenewswire.comEvaxion announces business update and first quarter 2026 financial resultsglobenewswire.comMay 7

globenewswire.comEvaxion to announce business update and first quarter 2026 financial results on May 7, 2026globenewswire.comMay 4

globenewswire.comEvaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officerglobenewswire.comApr 27

Trade EVAX

About Evaxion Biotech A/S

Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.

CEO: Helen Katrina Tayton-Martin
IPO Date: Feb 5, 2021

Market Data

Open: $3.32
High: $3.41
Low: $3.05
Volume: 41.6K
Avg Volume: 30.6K
52W High: $12.15
52W Low: $2.25

Valuation

Market Cap: $19.3M
Enterprise Value: $3.5M
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$6.7M
Revenue: $7.5M
Net Income: -$7.7M
Cash: $23.2M
Debt: $7.5M

Events

EarningsAug 13

EPS est. -0.01